Fangda Partners 'always showcases a high level of professionalism and commitment to best-practice'. The 12-partner team has 'an exceptional understanding of the life sciences industry and is able to cover all of the key areas relevant to this field'. In recent work, the group advised on global pharmaceutical companies' merger and antitrust matters, equity financing, Covid-19 vaccine licensing deals, establishing a regulator framework for clinical trials, engaging with NGOs, overseas listings, patent infringement, and government investigations. Its client roster features a large number of multinational pharmaceutical companies and investment funds that specialise in the healthcare sector. Josh Shin and Diana Li focus on M&A transactions; Michael Han handles competition-related matters; Kate Yin is recommended for regulatory compliance; and Fang Qi focuses on IP-related transactions and litigation. They jointly lead the life sciences and healthcare group, which bolstered its regulatory expertise with the hire of Jason Wu who joined from Global Law Office in 2020. Hong Kong-based Vanessa Cheung is also noted for corporate and commercial transactions. Sherry Yao is another key name.
Life sciences and healthcare: PRC firms in China
‘Fangda team always showcases a high level of professionalism and their commitment to best-practice. The team has an exceptional understanding of the life sciences industry and is able to cover all of the key areas relevant to this field. They took the time to understand our products and our company’s comparative advantage, and could perfectly meet our needs.’
‘Thoughtful, responsive and professional are the words that come to mind when I think of Josh. Finding someone who always has sight of the bigger picture while diving into the smallest details to ensure the quality of work product is not easy. Josh Shin has distinguished himself for his professionalism, enthusiasm to the career and sensitivity of industry, and I would recommend him to other colleagues without the slightest hesitation.’
‘The firm works as a team with a very deep bench serving clients with almost all needs. The quality, thoroughness and responsiveness of the team is extraordinary. Highly recommended for life sciences and healthcare companies.
‘The team has very broad exposure to most legal issues for life sciences companies. They are creative in solving difficult issues and stand out for their creative legal solutions.’
‘The feedback is timely, the legal opinions are forward-looking, and combine business needs.‘
Hasico Pharmaceutical Group
Hais Thera Scientific Fund I
Yunfeng Fund II
Everbright Healthcare Fund
Shanghai Kehua Bioengineering
EdiGene Beijing Biotechnology
LifeTech Scientific Corporation
Wuxi JW Therapeutics
CICC Healthcare Fund
CR-CP Life Science Fund
Hosen Healthcare Capital
Johnson & Johnson
Smith & Nephew
CMS (China Medical System)
- Advised AstraZeneca on a licensing deal with Shenzhen Kangtai Biological Products Co., Ltd., under which AstraZeneca will license the adenovirus vector-based COVID-19 vaccine, AZD1222, to BioKangtai.
- Acted for Mylan N.V. (Nasdaq: MYL), on its global merger with Upjohn, the off-patent branded and generic established medicine business of Pfizer, creating a new global pharmaceutical company, Viatris.
- Assisted Visen with establishing the entire set of regulatory systems regarding various aspects of its operation (especially the clinic trials), including code of conduct, internal training, SOPs, regulatory advice, and contract templates.
Global Law Office's practice spans advice to clinical research organisations, pharmaceutical and life sciences companies, biotechnology and medical devices clients, supply producers and distributors. The group assists with securities offerings and Greenfield and other investments and it also has notable expertise advising on the reform and restructuring of public hospitals, and M&A of privately-owned hospitals. The team is particularly active in advising both pharmaceutical companies and investment funds on multimillion-RMB financing transactions. Alan Zhou and Michael Yu lead the firm's 25-partner team from its Shanghai and Beijing offices respectively. Zhou's main clients include multinational corporations, well-known Chinese state-owned and private enterprises, private equity groups and venture capital funds; Yu focuses on private equity investments, securities offerings and foreign direct investment. Other names to note include Charlene Huang who focuses on cross-border license deals, hospital management and data protection matters; Coco Fan and Jacky Li who excel in regulatory and compliance, anti-corruption and antitrust matters; and of counsel Felicia Wang who advises on clinical trial and data protection.
‘The team understands the business model and business practices of the life science industry and is experienced in supporting licensing and M&A transactions. Equipped with lawyers of different levels, the billing method is flexible.’
‘Allan Zhou can also give pragmatic legal advice on relatively new topics, such as data compliance.’
Johnson & Johnson
- Advised CanSino Bio on a multi-centre clinical trial, including drafting and reviewing clinical trial agreements between the client and different parties.
- Acted for Shanghai Pharma on its licensing-in deal with Immvira for an anti-tumour drug at approx. RMB1.15bn.
- Advised Synermore Biomedicine (Suzhou) on the RMB2.64bn acquisition by Nucien Pharmaceutical, an A-shares listed company on the Shanghai STAR Market.
King & Wood Mallesons
King & Wood Mallesons‘ sizeable healthcare team is well equipped to advise large international healthcare companies across the whole life cycle of a product. Its broad offering spans the establishment of various types of entities, M&A, financing, restructuring, IPO, intellectual property protection, environmental-related issues for pharmaceutical manufactures and related disputes. It also has expertise advising pharmaceutical companies on cybersecurity and data protection issues including cross-border transfer of medical-related data and personal information. Recent mandates saw the team advising on a number of big-ticket IPOs on the A-share capital market, Shanghai Stock Exchange and Hong Kong Stock Exchange, as well as handling government investigations regarding alleged commercial bribery and advertising violations. The team is jointly led by Jianping Wang and Jianwen Huang from the firm's Beijing office; the latter focuses on corporate and M&A, international trade and compliance matters and is supported by well-regarded IP practitioners Tina Tai and Wenping Chen, both have a solid track record of representing industry-leading companies in high-profile patent invalidation and infringement litigation. Yimin Gao and Shanghai-based Mark Zhang are the key names to note for M&A mandates. Ting Liu, Fan Yang and Yuanyuan Zhu are other key contacts.
Other key lawyers:
‘They have a comprehensive offering covering R&D, promotion, compliance, anti-monopoly, dispute resolution and other services.‘
‘The team has a comprehensive risk prevention and control awareness, and can consider the business needs of the company, and put forward pertinent and practical suggestions.’
‘Fan Yang has comprehensive professional knowledge and has strong ability in project management and deployment.‘
‘Mark Zhang has comprehensive risk prevention and control awareness, and can consider the business needs of the enterprise, and put forward pertinent and practical suggestions.‘
RemeGen Co., Ltd.
Sinocelltech Group Limited
Kangji Medical Holdings Limited
Luoxin Pharmaceuticals Group Stock Co., Ltd
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Venus Medtech (Hangzhou) Inc.
Aesthetic Medical International Holdings Group Ltd.
Beijing Leto Laboratories Biotechnology Co., Ltd.
- Advised RemeGen on its H-share listing on the Main Board of the Hong Kong Stock Exchange.
- Assisted AstraZeneca with reaching a strategic cooperation agreement with Swiss OM Pharma where AstraZeneca is granted the exclusive right to import, distribute and promote OM Pharma’s Broncho-Vaxom.
- Advised Sinocelltech Group on its listing on the Shanghai Stock Exchange and the offering of new A shares.
Zhong Lun Law Firm‘s client list features a large number of multinational and domestic pharmaceutical, medical devices and medtech companies, as well as private equity and venture capital firms. The team is regularly instructed on multimillion-RMB domestic and overseas capital markets, financing, restructuring, patent litigation, licensing, anti-corruption and compliance investigation matters. Its recent caseload also includes the team representing pharmaceutical and life sciences companies in a range of disputes concerning contractual, distributorship, clinical trials, medical liability, monopoly, and unfair competition matters. IP practitioner Helen Cheng, Changyu Fu who specialises in dispute resolution, compliance and antitrust investigations, Jim Qiu who focuses on compliance matters, Dongmei Wang and Yongbin Ge jointly lead the team, which also includes Yuru Zuo.
‘The team understands the business model and business practices of the life sciences industry. The team has lawyers of different levels and has flexible billing methods.‘
‘Jim Qiu has a good understanding of the business model and business practices of the life science industry, patiently listens to the needs of clients, and actively provides solutions and alternatives to problems. Qiu responds to the urgent needs of customers in a timely manner.’
‘The team is committed to providing legal support for companies in the field of life sciences and health, including foreign-funded pharmaceutical companies and local biotech innovation companies.‘
‘The team of lawyers is very professional in the medical and health field. At the same time, it can also provide very professional and effective support for the Internet industry, data compliance, intellectual property and other fields. Its team can keenly discover the needs of customers in terms of business demands and will strive to provide solutions and guidance that can solve problems from the perspective of clients.‘
‘Shaun Gao impressed us a lot. He has a good understanding of life sciences and the healthcare industry and can always provide valuable advice to facilitate our transactions.‘
‘Changyu Fu has very rich experience in the field of pharmaceutical compliance. Whether it is related to corporate compliance or dispute resolution, he is a very professional lawyer; he can provide good compliance support to the legal affairs of pharmaceutical companies.‘
Ascendent Capital Partners
L Catterton Asia
Zai Lab Limited
Eli Lilly and Company
EUSA Pharma (UK) Limited
Global Health Drug Discovery Institute
Exegenesis Bio, Inc.
KOBAYASHI Pharmaceutical Co., Ltd
Shenzhen Kangtai Biological Products Co.,Ltd.
Bioray Laboratories Inc.
Beaufour-IPSEN (Tianjin) Pharmaceutical Co., Ltd.
Anhui Huami Information Technology Limited
Novogene Co., Ltd.
GlaxoSmithKline (China) R&D Co., Ltd.
Shanghai Roche Pharmaceuticals Ltd.
Fangcun Doctor (Beijing) Technology Co. Ltd.
Haisen Biopharmaceutical Co., Ltd.
Pediatrix Therapeutics (Shanghai) Co. Ltd.
Guanlan Network (Hangzhou) Co., Ltd.
Align Technology (Shanghai) Trading Co., Ltd.
Nutritional Growth Solutions Ltd.
Guangdong Wencan Die Casting Co.
Dizal (Jiangsu)Pharmaceutical Co.,Ltd.
SDIC Fund Management Co., Ltd
Exegenesis Bio Inc.
The Carlyle Group
Novogene Corporation Inc.
CBC Group and GT Fund
Lilly Asia Ventures
Beijing Konruns Pharmaceutical Co., Ltd. (“Konruns”)
Endeavour Consumer Health Limited
Shanghai Pharmaceuticals Holding Co., Ltd.
Hangzhou Tigermed Consulting Co., Ltd.
BVCF Management, Ltd.
Shanghai Cell Therapy Group Co., Ltd.
Genova Bio-Technology (Qingdao) Co., Ltd.
Beijing Dongfang Biotech Co., Ltd.
Xinjiang Deyuan Biological Engineering Co., Ltd.
Jiangsu Longliqi Bioscience Co., Ltd.
- Advised NetEase on its offering and secondary listing in Hong Kong.
- Advised Pediatrix Therapeutics (Shanghai) on the regulatory matters in relation to the approval of experimental research project with NMPA as well as other compliance matters related to controlled drugs in China.
- Advised Antengene Corporation on its initial public offering of shares in the Hong Kong Stock Exchange.
Han Kun Law Offices is particularly noted for its wealth of experience acting for major funds on their multibillion-dollar investments in China’s healthcare sector. The team is regularly instructed on compliance and regulatory, competition, intellectual property and litigation matters. Recent highlights also include advising companies, underwriters, and sponsors on onshore and offshore capital markets transactions, and acting for pharmaceutical companies on their license-in projects. Led by Yinshi Cao, who ‘understands life sciences and the healthcare sector from both the industry and legal perspective', the team includes Charles Li who specialises in public and private financing, M&A, restructuring and IP protection matters, and Min Zhu who focuses on regulatory, cybersecurity and data compliance matters, and counts both multinational and domestic companies as his key clients. Aaron Zhou is another name to note.
‘Hankun is one of our most favoured law firms while conducting investment deals in life sciences and healthcare. Hankun shows its insight into this industry as well as a good understanding of our requests and concerns. We always have good experiences working with its professional team smoothly.‘
‘Yinshi Cao understands life sciences and the healthcare sector from both the industry and legal perspective. He leads a responsive team, always delivering work efficiently and providing valuable advice to facilitate deals moving forward.‘
Innovent Biologics, Inc.
- Represented the joint sponsors and the underwriters (BofA Securities, Haitong International, and UBS) in JD Health International’s $3.41bn Hong Kong IPO.
- Advised Huaxing Growth Capital on its investment in MGI’s $1bn Series-B Financing.
- Represented AstraZeneca and CICC Capital in the formation and fundraising of a joint venture RMB Fund focusing on investments in the biotech and life sciences industries.
JunHe is well placed to advise on high-profile IPO and private equity investments, and M&A transactions for a mix of pharmaceutical companies and institutional investors, leveraging its strength and market-leading position advising on big-ticket mandates. Led by Shanghai-based Xudong Tao, the 30-partner team includes Ning Liu and Cathy Cai who are recommended for cross-border M&A, as is Feng Zhou who also has expertise in compliance, bribery investigation, antitrust and export control. The team also regularly acts as IP counsel on IPO transactions where it advises on the IP due diligence in the pre-IPO financing stage, and responds to IP-related queries concerning the Hong Kong Stock Exchange; Zhaohui Wang and Sophia Wu are the key names to note in this space.
‘Liu Ning’s team knows the industry background very well and understands the needs of our company. For the issues raised by our company, they often think from a big perspective and give us practical legal advice.’
I-MAB BIOPHARMA – Cayman
Shanghai Pharmaceuticals Holding Co., ltd.
Suzhou Zelgen Biopharmaceuticals Co., Ltd.- China
Bio-Thera Solutions, Ltd. – China
Grifols, SA – Spain
China Life Equity Investment Company Limited-China
Nanjing Legend Biotech Co., Ltd. – China Legend Biotech Corporation – Cayman
Shanghai Haihe Pharmaceutical Co., Ltd. – China
Zai Laboratories – China
- Assisted Nanjing Legend Biotech with the IPO of the American Depositary Shares.
- Advised Sino Biopharmaceutical Limited – Hong Kong on its $515m capital contribution to Sinovac R&D for the further development, capacity expansion and production of the 2019-nCoV inactivated vaccine CoronaVac™ as well as other development and operation activities of Sinovac R&D.
- Acted as PRC counsel to the co-sponsors Goldman Sachs and UBS Securities on New Horizon Health Limited’s issuance and listing on the Main Board of the Hong Kong Stock Exchange, raising more than HK$2bn.
Leveraging its track record in financing and capital markets transactions, Haiwen & Partners’ team advises life sciences and healthcare companies on issuance and listing of stocks in the Chinese mainland and overseas, multimillion-RMB financing transactions, and domestic and overseas bond issuance and other securities-related services. It counts sponsors, funds and financial institutions as well as biotechnology, listed pharmaceutical and medical devices companies as clients. Tina Wu leads the team from the firm's Shanghai office, and is hugely experienced in regulatory and compliance issues concerning clinical and non-clinical research, product development, commercialisation and market access strategies, post-market compliance and enforcement actions. Frank Wang and Hanguo Zhang focus on patent disputes and protection matters. Hao Bian, Wehzhen Dai, Jieni Gu, Jiping Zhang and Xuemei Lu are the key names to note for transactional matters.
Other key lawyers:
The Joint Sponsors (i.e. Goldman Sachs (Asia) L.L.C.; China International Capital Corporation Hong Kong Securities Limited) and the Underwriters
Ping An Insurance (Group) Company of China
JHBP (CY) HOLDINGS LIMITED
China International Capital Corporation Limited
Temasek NoWarburg Pincus
China Life Healthcare Fund
Ruipeng Pet Group Inc.
Neusoft Xikang Holdings Inc.
Credit Suisse (Hong Kong) Limited
- Advised Temasek on the privatisation of Taikang Biologic Group.
- Advised Ping An Insurance (Group) Company of China on its acquisition of 2.05% stakes in Shionogi & Co and establishing 7joint ventures in Hong Kong and Shanghai.
- Advised the lead investor Warburg Pincus on its participation in Gaush Meditech’s Series-B financing.
Shihui Partners entered the ranking this year following its significant expansion in this space with the recent recruitment of 12 partners from red circle firms. Clients praise its 'in-depth understanding of the healthcare and life sciences industry and development trends, as well as solid professional background knowledge and rich legal practice experience'. The team is well equipped to handle compliance projects in pharmaceutical research and development, product registration, exclusive product promotion, technology licensing and compliance system construction, as well as transactional matters including private financing, M&A, restructuring, and IPOs. Its clients include several well-known domestic and international medical companies and investment institutions. Practice head Xiangjun Kong is able to leverage his previous position as head of legal counsel at Sanofi (China) Investment Co. to assist with compliance, M&A and corporate financing matters, among others.
‘Xiangjun Kong, Jiani Wang and Jing Ran can give us legal advice that best fits business practices, and the opinions provided are very efficient and professional every time.’
‘As a senior expert in the medical field, the partners of the Shihui Life and Health team have a very deep professional foundation and rich professional experience. Compared with other law firms, the Shihui Life and Health team can accurately predict the actual needs of legal affairs, business and other cross-departmental colleagues when providing daily legal consultations, and analyse the laws involved from different angles from the perspective of business purposes. They give systematic and individual analysis opinions and solutions.‘
Orchid Asia Group Management Ltd.
Burning Rock Biotech Ltd.
Genetron Holdings Ltd.
Omniscience Holdings Ltd. and several other pre-IPO investors
- Advised Orchid Asia Group Management on the RMB1bn series-C financing of Med-Zenith.
- Advised Burning Rock Biotech on a series of financing, IPO and post-IPO capital increase matters.
Leveraging its market-leading capital markets expertise and a particular strength in the biotech space, Tian Yuan Law Firm‘s 15-partner life sciences team is regularly called upon to handle domestic and overseas listings, investment and financing, and M&A transactions. In 2020, it advised Shanghai Junshi Biosciences and CanSino Biologics on their mega IPOs on the Science and Technology Innovation Board of Shanghai Stock Exchange. Recent highlights also include advising on compliance, government investigations, antitrust and anti-commercial bribery matters. Siqi Fu and Juanjuan Song jointly lead the team from its Beijing headquarters and are supported by Shanghai-based Ping Xu.
‘The counsels in Tianyuan are extremely experienced, knowledgeable, and client-friendly.‘
‘Siqi Fu is the most well-known expert in the legal field. He is highly recognised for his technical skillsets as well as commercial impact.‘
CanSino Biologics Inc. (“CanSino”)
Simcere Pharmaceutical Group
Kangji Medical Holdings Limited
Hygeia Healthcare Holdings Co., Limited
RemeGen Co., Ltd.
Raily Aesthetic Medicine International Holdings Limited
JOINN Laboratories, Inc.
Sciclone Pharmaceuticals (Holdings) Limited
New Journey Healthcare Group
- Advised on Simcere Pharmaceutical’s Hong Kong IPO.
- Handled Shanghai Junshi Biosciences Junshi BioPharma’s IPO on the Science and Technology Innovation Board of Shanghai Stock Exchange.
- Advised New Journey Healthcare Group on the acquisition of six large hospitals and several basic-level medical institutions owned by Sichuan Coal Industry Group.